Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.
The interim analysis at week 10 shows the first two administrations of the HGP-30 AIDS vaccine to be safe in HIV infected patients. Proof of safety of HGP-30 in HIV infected individuals is the primary goal this study was designed to achieve. Further, when evaluated as a group, disease stabilization during the 10 week evaluation period was seen in patients with a CD4 count between 300 and 750. The number of patients with a CD4 count between 50 and 300 is too small to make a generalized statement.
The study is expected to be completed by the Summer of 1997.
Based on these interim results, CEL-SCI Corporation is currently preparing for additional HGP-30 studies in Thailand. Those tests are expected to start in the second half of 1997. Additional studies in the U.S. are also under investigation.
At the International Conference on AIDS this past Summer, Dr. James Kahn of San Francisco General Hospital reported protection against HIV infection using the blood of five HGP-30 vaccinated, non-infected volunteers in SCID mice. This is the first time that protection by an AIDS vaccine has been demonstrated with a HIV challenge model.
CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based treatments for cancer, AIDS and tuberculosis. Recently, CEL-SCI Corporation signed a collaborative agreement with the U.S. Navy to jointly develop a malaria vaccine and a collaboration agreement with Northeastern Ohio University College of Medicine to jointly develop a herpes vaccine.
CONTACT: Geert Kersten, Chief Executive Officer of CEL-SCI Corporation 703-549-5293
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961031
PR961034
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .